Exozymes (EXOZ) Assets Average (2024 - 2026)
Exozymes (EXOZ) posted quarterly Assets Average of $6.8 million for Q4 2025, down 17.5% year-over-year from $8.3 million in Q4 2024, and down 21.3% quarter-over-quarter from $8.7 million in Q3 2025.
Exozymes (EXOZ) Assets Average (2024 - 2026) Analysis & Trends
Exozymes (EXOZ) has reported Assets Average for 2 consecutive years, with $6.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Assets Average fell 17.5% year-over-year to $6.8 million; the TTM figure through Dec 2025 stood at $6.8 million (down 17.5% YoY), while the FY2025 annual figure was $9.5 million, up 14.54% from the prior year.
- Assets Average fell to $6.8 million in Q4 2025 per EXOZ's latest filing, from $8.7 million in the prior quarter.
- Across five years, Assets Average topped out at $12.3 million in Q1 2025 and bottomed at $6.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Exozymes | 62.35 Mn | 62.35 Mn | - | 6.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.98 Mn |
| Dec 31, 2025 | 6.85 Mn |
| Sep 30, 2025 | 8.70 Mn |
| Jun 30, 2025 | 10.60 Mn |
| Mar 31, 2025 | 12.28 Mn |
| Dec 31, 2024 | 8.30 Mn |